Fairfield, Bush & Co. Biogen Inc. Transaction History

Fairfield, Bush & Co.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$256.56 - $292.34 $1.8 Million - $2.05 Million	7,000 New	7,000 $1.95 Billion
Q1 2022 May 06, 2022	BUY	$193.77 - $244.14 $1,937 - $2,441	10 New	10 $2,000
Q4 2021 Feb 09, 2022	SELL	$223.92 - $287.77 $1.57 Million - $2.01 Million	-7,000 Closed	0 $0
Q3 2021 Nov 08, 2021	BUY	$282.99 - $369.05 $1.98 Million - $2.58 Million	7,000 New	7,000 $1.98 Million
Q2 2021 Aug 02, 2021	SELL	$259.0 - $414.71 $1.81 Million - $2.9 Million	-7,000 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$216.71 - $338.96 $650,130 - $1.02 Million	-3,000 Reduced 30.0%	7,000 $1.66 Million
Q2 2017 Aug 15, 2017	BUY	N/A	10,000	10,000 $2.71 Million

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Fairfield, Bush & Co., based on Form 13F filings with the SEC.

Stay updated on Fairfield, Bush & Co. with notifications on news.